പ്രോട്ടീൻ സമന്വയിപ്പിക്കുന്നതിന് ഉപയോഗിക്കുന്ന അമിനോ ആസിഡിന്റെ മാലിന്യങ്ങൾ
ഉൽപ്പന്ന വിശദാംശങ്ങൾ
| NO | ഉൽപ്പന്നങ്ങൾ | കളുടെ നമ്പർ | പ്രധാന ഗുണനിലവാരമുള്ള സൂചകം | |||
| വിശുദ്ധി | പരമാവധി. അശുദ്ധി | ആകെ ലായക അവശിഷ്ടം | ഈര്പ്പം | |||
| 1 | Fmoc-β-ala-ala-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 2 | FMOC-D-ALA-D-ALA-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 3 | Fmoc-β- ala-d-ala-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 4 | FMOC-ARG (PBF) -ARG (PBF) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 5 | Fmoc-β- Ala-ARG (PBF) -O | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 6 | Fmoc-D-Art (PBF) -d-ARD (PBF) -ഓ | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 7 | Fmoc-β- Ala-d-Art (PBF) -ഓ | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 8 | Fmoc-homarag (PBF) -homaarg (PBF) -ഓമോഗ് | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 9 | Fmoc-β- Ala-HomOarg (PBF) -O | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 10 | Fmoc-Asn (TRT) --asn (trt) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 11 | Fmoc-ala-ann (trt) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 12 | FMoc-asp (OTBU) --asp (Otbu) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 13 | Fmoc-β- Ala-asp (OTBU) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 14 | എഫ്എംഒസി-സിസ് (ട്രസ്റ്റ്) -സികൾ (ട്രസ്) -ഓ | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 15 | FMoc-β- ALA-CYS (TRT) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 16 | എഫ്എംഒസി-സിസ് (എസിഎം) -സികൾ (എസിഎം) -ഓ | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 17 | Fmoc-β- ALA-CYS (ACM) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 18 | Fmoc-gln (trt) -ln (trt) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 19 | Fmoc-β- Ala-gln (Trt) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 20 | Fmoc-glu (Otbu) -gu (Otbu) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 21 | Fmoc-β-ala-glu (Otbu) -oh.h2o | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 22 | Fmoc-β-ala-gly-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 23 | എഫ്എംഒസി-അദ്ദേഹത്തിന്റെ (ട്രസ്) -ഹിസ് (TRT) -ഓ | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 24 | Fmoc-β-ala-hant (trt) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 25 | FMOC-ile-ile-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 26 | Fmoc-β- Ala-ile-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 27 | Fmoc-leu-ടു-ഓ | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 28 | FMOC- β- ALA-ടു-ഓ | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 29 | Fmoc-d-leu-d-ടു-ഓ | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 30 | FMOC- β- ALA-D-ടു-ഓ | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 31 | എഫ്എംഒസി-ലൈസ് (BOC) -lys (Boc) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 32 | എഫ്എംഒസി-β-ala-lys (Boc) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 33 | എഫ്എംഒസി-ലൈസ് (അലോക്ക്) -ലൈസ് (അലോക്ക്) -ഓ | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 34 | Fmoc-β-ala-lys (Alocc) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 35 | Fmoc-med-me-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 36 | FMOC- β- ALA-MET-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 37 | Fmoc-orn (Boc) --orh (BOC) -ഓ | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 38 | Fmoc-β- Ala-orn (Boc) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 39 | FMOC-PHE-PHE-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 40 | Fmoc-β-ala-phe-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 41 | FMOC-D-PHE-D-PHE-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 42 | FMOC- β- ALA-D-PHE-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 43 | Fmoc-pro-പ്രോ-ഓ-ഓ | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 44 | FMOC- β- ALA- PRO-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 45 | Fmoc-Ser (tbu) -സർ (Tbu) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 46 | FMoc-β- Ala-SE (tbu) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 47 | FMoc-SER (TRT) -സർ (TRT) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 48 | FMoc-β- ALA-SE (TRT) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 49 | എഫ്എംഒസി-ത്രോ (ടിബിയു) -ഇത് എർത്ത് (ടിബിയു)- | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 50 | Fmoc-β- Ala-ത്രോ (Tbu) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 51 | Fmoc-trp (Boc) -trp (BOC) -ഓ | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 52 | FMoc-β- Ala-trp (BOC) -ഓ | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 53 | Fmoc-D-Trp (BOC) -d-trp (BOC) -ഓ | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 54 | Fmoc-β- Ala-D-Trp (BOC) -ഓ | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 55 | Fmoc-tyr (tbu) -ter (tbu) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 56 | Fmoc-β-ala-tyr (tbu) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 57 | Fmoc-d-tir (et) -d-tir (et) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 58 | Fmoc-β- Ala-d-tri (et) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 59 | FMoc-Tr (ME) -tyr (me) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 60 | Fmoc-β-ala-tyr (me) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 61 | Fmoc-wall-sal-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 62 | Fmoc-β-Ala-wal-Oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 63 | FMOC-D-CIT-D-DIT-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 64 | FMOC- β- ALA-D-CIT-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 65 | FMOC- β- ALA-DAB-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 66 | Fmoc- (3- (2-നാഫ്ത്തിൽ) -d-ala) 2-ഓ | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 67 | Fmoc-β-ala-3- (2-Naffthyl) -d-ala-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 68 | Fmoc- (3- (3-pyridine) -d-ala) 2-ഓ | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 69 | Fmoc-β-ala-3- (3-pyridine) -d-ala-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 70 | FMOC- (4-CHLOO-D-PHE) 2-ഓ | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 71 | Fmoc-β-ala-4-chloro-d-phe-Oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 72 | FMOC- (D-4iph (tbucm)) 2-ഓ | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 73 | Fmoc-β- Ala-d-4-4h (Tbucm) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 74 | FMoc-APH (L-hoor)--oh (l-hor hort) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 75 | FMoc-β- Ala-aph (l-hor hort) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 76 | എഫ്എംഒസി-ലൈസ് (ഐപിആർ, ബോക്ക്) -ലൈസ് (ഐപിആർ, BOC) -ഓ | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 77 | എഫ്എംഒസി-β-ala-lys (ipr, Boc) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 78 | FMOC- β- ALA-AEEA-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 79 | Fmoc-aib-aib-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 80 | FMOC- β- ALA-AIB-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 81 | FMOC-ADG-OH | 91000-69-0 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 82 | എച്ച്-ആർഗ് (പിബിഎഫ്) -ഓ | 200115-86-2 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 83 | FMOC-D-ARG-OH | 130752-32-8 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 84 | എച്ച്ഡി-ആർഗോ (പിബിഎഫ്) -ഓ | 200116-81-0 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 85 | Fmoc-homarag-oh.hcl | 208174-14-5 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 86 | എച്ച്-ഹോമോറാഗ് (പിബിഎഫ്) -ഓ | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 87 | FMOC-D-HomOARG-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 88 | എച്ച്ഡി-ഹോമോറാഗ് (പിബിഎഫ്) -ഓ | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 89 | FMOC-ASN-OH | 71989-16-7 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 90 | H-ASN (TRT) -oh | 132388-58-0 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 91 | Fmoc-asp-oh | 119062-05-4 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 92 | H-asp (OTBU) -oh | 3057-74-7 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 93 | Fmoc-cys-oh | 135248-89-4 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 94 | എച്ച്-സിഐഎസ് (ട്രസ്) -ഓ | 2799/7/7 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 95 | എച്ച്-സിഐഎസ് (എസിഎം) -oh.hcl | 28798-28-9 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 96 | Fmoc-gln-oh | 71989-20-3 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 97 | H-gln (TRT) -oh | 102747-84-2 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 98 | Fmoc-glu-oh | 121343-82-6 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 99 | എച്ച്-ഗ്ലൂ (ഒടിബി) -oh.h2o | 2419-56-9 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 100 | Fmoc-high ഓ | 116611-64-4 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 101 | H-അവന്റെ (TRT) -oh | 35146-32-8 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 102 | BOC-heal-OH | 17791-52-5 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 103 | Fmoc-lys-oh | 105047-45-8 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 104 | എച്ച്-ലൈസ് (BOC) -oh | 2418-95-3 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 105 | എച്ച്-ലൈസ് (അലോക്ക്) -ഓ | 6298/3/9 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 106 | Fmoc-orn-oh.hcl | 201046-57-3 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 107 | H-orn (Boc) -oh | 13650-49-2 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 108 | FMOC-SER-OH | 73724-45-5 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 109 | എച്ച്-സെർ (ടിബിയു) -ഓ | 18822-58-7 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 110 | എച്ച്-സെർ (ട്രസ്റ്റ്) -ഓ | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 111 | Fmoc-ത്രോ-ഓ. H2o | 73731-37-0 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 112 | എച്ച്-ത്രോ (ടിബിയു) -ഓ | 4378-13-6 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 113 | FMOC-TRP-OH | 35737-15-6 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 114 | എച്ച്-ട്രപ് (BOC) -oh | 146645-63-8 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 115 | FMOC-D-TRP-OH | 86123-11-7 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 116 | എച്ച്ഡി-ട്രൂപ്പ് (BOC) -ഓ | 201290-11-1 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 117 | FMOC-TYR-OH | 92954-90-0 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 118 | എച്ച്-ടാർ (ടിബിയു) -ഒ | 18822-59-8 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 119 | FMOC-D-TIR-OH | 112883-29-1 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 120 | എച്ച്ഡി-ടാർ (et) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 121 | എച്ച്-ടാർ (ഞാൻ) -oh.hcl | 67423-44-3 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 122 | Fmoc-d-4hap (cbm) -oh | 324017-22-3 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 123 | എച്ച്ഡി-4hap (tbucm) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 124 | എഫ്എംഒസി-ലൈസ് (IPR) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 125 | എച്ച്-ലൈസ് (ഐപിആർ, BOC) -ഓ | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
കുറിച്ച്
നഷ്ടപരിഹാരം
മാന്യ്യേദനം വലിയ ഗുണനിലവാരമുള്ള ഉൽപ്പന്നങ്ങൾ നൽകുന്നു, ആവശ്യത്തിന് തെളിവുകൾ ഉപയോഗിച്ച് ആവശ്യമായ സമയപരിധിക്കുള്ളിൽ, ആവശ്യമായ സമയപരിധിക്കുള്ളിൽ ഏതെങ്കിലും ഉൽപ്പന്ന നിലവാരം ഉയർത്തുന്നുവെങ്കിൽ, നഷ്ടപരിചയങ്ങളുടെ നടപടിക്രമങ്ങൾ പ്രവർത്തനക്ഷമമാക്കുന്നതിന് ആവശ്യമായ വിശകലനവും മൂല്യനിർണ്ണയവും ഞങ്ങൾ നൽകും.
നിര്മ്മാണം
ഫാർമസ്യൂട്ടിക്കൽ ഉൽപ്പന്നങ്ങളുടെ ശേഷി ടൺ ഗ്രേഡിലെത്തി, രാസ ഉൽപ്പന്നങ്ങളുടെ ശേഷി 100 ടൺ + ഗ്രേഡിൽ എത്തുന്നു, ലോകമെമ്പാടും ക്ലയന്റുകൾ നൽകുന്നതിന് കഴിവുകൾ നന്നായി സജ്ജീകരിച്ചിരിക്കുന്നു.
ഗവേഷണവും വികസനവും
ടാർഗെറ്റുകൾ സജ്ജമാക്കുമ്പോൾ, വിവിധ പുതിയ ഉൽപ്പന്നങ്ങൾ വികസിപ്പിക്കുന്നതിന് ഗവേഷണ-വികസന ടീം സ്ഥാപിച്ച പദ്ധതിയുണ്ട്, ടീമിലെ ഓരോ അംഗവും കെപിഐ ഉത്തരവാദിത്തവും പ്രോത്സാഹന നയവുമായി തുടരേണ്ടിവരും.
